Establishment Labs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07 2025 - 7:00AM
Business Wire
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global
medical technology company dedicated to improving women’s health
and wellness, principally in breast aesthetics and reconstruction,
today announced that Juan José Chacón-Quirós, Founder and Chief
Executive Officer, and Raj Denhoy, Chief Financial Officer, will
present at the 43rd Annual J.P. Morgan Healthcare Conference on
Wednesday, January 15, 2025 at 3:45 p.m. Pacific Time.
A live webcast of the presentation will be available on the
Establishment Labs investor relations website at
https://investors.establishmentlabs.com/. An archived version of
the webcast will be available on the same website following
completion of the event.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology
company dedicated to improving women’s health and wellness through
the power of science, engineering, and technology. The Company
offers a portfolio of Femtech solutions for breast health, breast
aesthetics and breast reconstruction. The nearly four million
Motiva® devices Establishment Labs has delivered to plastic and
reconstructive surgeons since 2010 have created a new standard for
safety and patient satisfaction in the over 85 countries in which
they are available. The Motiva Flora® tissue expander is used to
improve outcomes in breast reconstruction following breast cancer
and it is the only regulatory-approved expander in the world with
an integrated port using radio-frequency technology that is MRI
conditional. Mia Femtech™, Establishment Lab’s unique minimally
invasive experience for breast harmony, is the Company’s most
recent breakthrough innovation. These solutions are supported by
over 200 patent applications in 20 separate patent families
worldwide and over 100 scientific and clinical studies and
publications in peer reviewed journals. Establishment Labs
manufactures at two facilities in Costa Rica compliant with all
applicable regulatory standards under ISO13485:2016 and FDA 21 CFR
820 under the MDSAP program. Please visit our website for
additional information at www.establishmentlabs.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250107356947/en/
Investor/Media Contact: Raj Denhoy 415-828-1044
rdenhoy@establishmentlabs.com
Establishment Labs (NASDAQ:ESTA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Establishment Labs (NASDAQ:ESTA)
Historical Stock Chart
From Jan 2024 to Jan 2025